Aclaris Therapeutics initiates Phase 1a/1b program for ATI-052

Aclaris Therapeutics (ACRS) has initiated a placebo-controlled Phase 1a/1b program for ATI-052, the Company’s potential best-in-class investigational bispecific anti-TSLP/IL-4R antibody. The program will consist of a Phase 1a single and multiple ascending dose portion in healthy volunteers, followed by an expected Phase 1b proof of concept portion. The randomized, blinded, placebo-controlled Phase 1a portion is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of subcutaneously administered ATI-052 initially in healthy adults receiving single ascending doses and multiple ascending doses. The Phase 1b proof-of-concept assessment in up to two undisclosed indications is expected to follow the Phase 1a SAD/MAD portion of the program.